Evaluate the Role of Currently Available Antifibrotic Agents in the Treatment of IPF and SSc-ILD

Access Activity

Overview / Abstract:

Program Overview

The management of progressing fibrotic pulmonary disease continues to evolve and guidelines are challenged to stay abreast of, and to reflect, advances from recent clinical studies or drug approvals. Clinicians need to be aware of this challenging landscape to develop treatment plans that are current and that help patients to achieve optimal outcomes. In this podcast, Drs. Zibrak and Saketkoo will review the evidence supporting the use of antifibrotic agents, specifically nintedanib and pirfenidone in patients with IPF and the emerging evidence that these drugs may be useful in SSc-ILD.

What is the role of currently approved antifibrotics in the treatment of PF-ILD?
What is the current status of antifibrotics?
Which patients with reduced lung function might be considered for treatment with antifibrotic therapy?
What is the current thinking with managing side effects associated with antifibrotic therapy?
Are there shared perspectives on treatment among rheumatology and pulmonary ILD specialists?

Learning Objectives

Upon completion of this activity, participants should be better able to:

Evaluate the role of currently available antifibrotic agents in the treatment of patients with pulmonary fibrosis associated with IPF and SSc-ILD.

Expiration

Aug 26, 2020

Discipline(s)

Nurse Practitioner , Physician CME, Physician Assistant CME

Format

Podcast

Credits / Hours

.5

Accreditation

ACCME

Presenters / Authors / Faculty

Joseph D. Zibrak, MD

Associate Professor of Medicine
Harvard Medical School
Director, ILD Center
Division of Pulmonology and Critical Care
Beth Israel Deaconess Medical Center
Boston, MA
Lesley Anne Saketkoo, MD, MPH

Associate Professor of Medicine
Tulane University School of Medicine
Clinical Immunology, Allergy and Rheumatology, Pulmonary Diseases, Critical Care and Environmental Medicine
Director, New Orleans Scleroderma & Sarcoidosis Patient Care & Research Center
Co-Director, UMC Comprehensive Pulmonary Hypertension Center
New Orleans, LA

Activity Specialities / Related Topics

Acute Care, Critical Care / Intensive Care, Emergency Medicine, Geriatrics / LTC, Oncology / Cancer / Radiation Therapy, Pathology, Pharmacology, Pulmonary Medicine / COPD, Radiology / Imagery / Nuclear Medicine

Sponsors / Supporters / Grant Providers

Boehringer Ingelheim Pharmaceuticals, Inc.

Keywords / Search Terms

Relias LLC ild, lung disease, ipf Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map